

Remarks

Withdrawn claim 19, and claims 25, 31, 37-56, 58, 63, 68, 73, and 77 have been cancelled without prejudice or disclaimer; Applicants reserve the right to pursue the canceled subject matter in one or more continuing applications. Claims 26-30, 32-36, 57 and 62 have been amended. In particular, allowed claims 26 and 32 have been amended into independent form, and the claims dependent on cancelled claims 25 and 31 have been amended to depend from claims 26 and 32. Allowed claims 57 and 62 have been amended to remove the phrase "30 contiguous amino acid residues of", as residues 19-47 are only 29 residues in length. No new matter has been introduced.

Applicants acknowledge and thank the Examiner for indicating the allowance of claims 26-27, 32-33, and 57-76.

Rejection Under 35 U.S.C. § 112, First Paragraph

The Examiner has rejected claims 25, 28-31, and 34-56 under 35 U.S.C. § 112, first paragraph, as allegedly failing to adequately describe the instant invention. Specifically, the Examiner asserts "the specification does not disclose and fully characterize the genus of any variant of the protein of SEQ ID NO: 139." Page 3, second paragraph.

In response, while Applicants disagree and maintain that the previously pending claims fully complied with 35 U.S.C. § 112, first paragraph, claims 25, 31, and 37-56 have been cancelled without prejudice or disclaimer, and claims 28-30 and 34-36 have been amended to depend from allowed claims 26 and 32, now in independent form. Accordingly, the rejection has been obviated, and Applicants respectfully request that the rejection be reconsidered and withdrawn.

Conclusion

Entry of the above amendment is respectfully solicited. In view of the foregoing remarks, Applicants believe that this application is now in condition for allowance, and an early notice to that effect is urged. The Examiner is invited to call the undersigned at the phone number provided below if any further action by Applicant would expedite the allowance of this application.


Finally, if there are any fees due in connection with the filing of this paper, please charge the fees to our Deposit Account No. 08-3425. If a fee is required for an extension

of time under 37 C.F.R. § 1.136, such an extension is requested and the appropriate fee should also be charged to our Deposit Account.

Dated: June 13, 2003

Respectfully submitted,

By


Mark J. Hyman

Registration No.: 46,789

HUMAN GENOME SCIENCES, INC.

9410 Key West Avenue

Rockville, Maryland 20850

(240) 314-1224

KKH/MMM/MJH/ba